Stifel Upgrades FibroGen (FGEN) to Buy
Tweet
Share
E-mailGet Alerts FGEN Hot Sheet
Price: $9.71 --0%
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Rating Summary:
4 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Join SI Premium – FREE
Stifel analyst Annabel Samimy upgraded FibroGen (NASDAQ: FGEN) from Hold to Buy with a price target of $28.00 (from $23.00).
For an analyst ratings summary and ratings history on FibroGen click here. For more ratings news on FibroGen click here.
Shares of FibroGen closed at $17.32 yesterday.
You May Also Be Interested In
- BofA Securities Upgrades Candel Therapeutics Inc. (CADL) to Buy
- RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform
- Mizuho Upgrades American Homes 4 Rent (AMH) to Outperform
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
